Galderma to develop new muscle relaxant product

Galderma is to expand its portfolio of muscle relaxant products with the development of a new agent based on an advanced formulation of botulinum toxin.

The first cohort of patients have already been treated in an initial clinical study of the drug that is expected to be completed soon, with a second trial set to commence before the end of the year.

Galderma believes this new therapy will allow it to capitalise on demand for muscle relaxants in territories where it does not promote Azzalure or Dysport in aesthetics, such as in North America.

Figures from research firm Medical Insights suggest that the market for muscle relaxants in aesthetics will be worth $1.21 billion (783.36 million pounds) in 2013, rising to $1.59 billion by 2017.

Humberto Antunes, president and chief executive officer of Galderma, said: "Muscle relaxants are a key medical solution aesthetic physicians can use to create balanced and optimal results for their patients."

In April 2013, the company expanded its European product portfolio with the launch of Pliaglis, a topical anaesthetic cream for use on skin prior to dermatological procedures.